Modality
siRNA
MOA
C5i
Target
EZH2
Pathway
RAS/MAPK
MS
Development Pipeline
Preclinical
~Mar 2011
→ ~Jun 2012
Phase 1
~Sep 2012
→ ~Dec 2013
Phase 2
~Mar 2014
→ ~Jun 2015
Phase 3
~Sep 2015
→ ~Dec 2016
NDA/BLA
~Mar 2017
→ ~Jun 2018
Approved
Sep 2018
→ Apr 2027
ApprovedCurrent
NCT06230615
1,930 pts·MS
2021-05→2026-11·Completed
NCT06001511
1,172 pts·MS
2022-06→2026-09·Terminated
NCT08982201
1,372 pts·MS
2018-09→2027-04·Completed
4,474 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-09-065mo awayPh3 Readout· MS
2026-11-158mo awayPh3 Readout· MS
2027-04-091.0y awayPh3 Readout· MS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Approved
Complet…
Approved
Complet…
Approved
Termina…
Catalysts
Ph3 Readout
2026-09-06 · 5mo away
MS
Ph3 Readout
2026-11-15 · 8mo away
MS
Ph3 Readout
2027-04-09 · 1.0y away
MS
CompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06230615 | Approved | MS | Completed | 1930 | BodyWt |
| NCT06001511 | Approved | MS | Terminated | 1172 | ORR |
| NCT08982201 | Approved | MS | Completed | 1372 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| Gelibrutinib | Sun Pharma | NDA/BLA | EZH2 | |
| RDY-3640 | Dr Reddy's | Preclinical | EZH2 | |
| QUO-6518 | Quotient Ther | Preclinical | CD38 |